Announcements Trials
Browse Landscape

Phase

Phase 1 25Phase 1/2 19Phase 3 6Phase 2 4Phase 4 2Phase 2/3 1

Status

Completed 2Active not recruiting 2Terminated 1Recruiting 1

Sponsor Class

INDUSTRY 6OTHER 1

Study Type

Interventional 6

Sponsor

Cancer Type

Lymphoid 3

Conditions

Arthritis, Rheumatoid 2Spondylitis, Ankylosing 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma 1

Interventions

Carboplatin 315Paclitaxel 303Cisplatin 250Docetaxel 238pembrolizumab 230Gemcitabine 214Pemetrexed 158Capecitabine 147Rituximab 144Bevacizumab 142Dexamethasone 125Fluorouracil 121Cyclophosphamide 102Trastuzumab 100Doxorubicin 96Nivolumab 93Prednisone 92Oxaliplatin 90atezolizumab 75Leucovorin 72durvalumab 69130-nm albumin-bound paclitaxel 68Injections 66Lenalidomide 63Irinotecan 62Bortezomib 56Letrozole 54Topotecan 53Fulvestrant 53Drug Therapy 50

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Phase 3 × INDUSTRY × tocilizumab × Clear all
NCT06084936 2026-06-03

GLOBRYTE

Hoffmann-La Roche

Phase 3 Recruiting
182 enrolled
Lymphoid

Lymphoma

NCT05171647 2026-05-07

SUNMO

Hoffmann-La Roche

Phase 3 Active not recruiting
208 enrolled 12 charts
Lymphoid

Lymphoma, Non-Hodgkin

NCT04408638 2026-04-07

A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Hoffmann-La Roche

Phase 3 Active not recruiting
270 enrolled
Lymphoid

Lymphoma, Large B-Cell, Diffuse

NCT02046603 2018-12-07

ACT-MOVE

Hoffmann-La Roche

Phase 3 Completed
162 enrolled 30 charts

Arthritis, Rheumatoid

NCT00883753 2014-08-06

An Extension to Study MA21573, Evaluating Tocilizumab in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Current Non-Biological DMARDs and/or Anti-tumor Necrosis Factor (TNF) Therapy

Hoffmann-La Roche

Phase 3 Completed
934 enrolled 40 charts

Arthritis, Rheumatoid

NCT01209689 2013-01-17

A Study of Tocilizumab (RoActemra/Actemra) in Patients With Ankylosing Spondylitis Who Have Had an Inadequate Response to Previous Tumor Necrosis Factor (TNF) Antagonist Therapy

Hoffmann-La Roche

Phase 3 Terminated
113 enrolled 7 charts

Spondylitis, Ankylosing

Data powered by HemOnc (CC BY 4.0) Colophon âš¡